Biogen’s recently FDA-approved drug Aduhelm costs an upward of $56,000 per year, and this may have a domino effect of impacts: “If Aduhlem is…
Following the FDA’s approval of the new Alzheimer’s drug Aduhelm (aducanumab), retired neurologist Daniel Gibbs spoke with Being Patient in a recent LiveTalk about…
The FDA’s approval of Biogen’s new anti-amyloid drug Aduhelm was a landmark moment for Alzheimer’s — and it comes with no small amount of…
Looking for answers about Alzheimer’s treatment Aduhelm (generic name aducanumab)? Here’s a primer on what it is, what it does, and more, according to…
As an aducanumab trial participant, Phil Gutis, a reporter with early-stage Alzheimer’s, was part of Aduhelm’s journey to FDA approval. Doctors can soon start…
Following the FDA’s approval of aducanumab, marketed under the name Aduhelm, an aducanumab trial principal investigator and a former aducanumab trial site investigator speak…
“Historic moment:” Today, the FDA gave Biogen’s investigational Alzheimer’s drug aducanumab its approval, with the requirement that they conduct a post-approval trial. In a…